Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog)

American Journal of Cardiology

Volumn 83, Issue 10, 1999, Pages 1506-1509

  Hradec, Jaromir ^a   Kral, Jiri ^a   Janota, Tomas ^a   Krsek, Michal ^a   Hana, Vaclav ^a   Marek, Josef ^a   Malik, Marek ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; DESMOPRESSIN; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETES INSIPIDUS; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HUMAN; HYPOPHYSECTOMY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RADIOTHERAPY; SLOW RELEASE FORMULATION;

ACROMEGALY; ADULT; FEMALE; HEART; HEART DISEASES; HORMONE ANTAGONISTS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 0033562525     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00135-6     Document Type: Article

References (21)

1. McGuffin WJ Jr, Sherman BM, Roth C, Gorden P, Kahn R, Roberts WC, Frommer PI. Acromegaly and cardiovascular disorders, a prospective study. Ann Intern Med1974;81:11-18.
2. Souadjian J.V., Schirger A. Hypertension in acromegaly. Am J Med. 254:1967;629-633.
3. Hejtmancik M.U., Bradfield J.Y., Herrmann G.R. Acromegaly and the heart a clinical and pathological study . Ann Intern Med. 34:1951;1445-1456.
4. Martins J.B., Kerber R.S., Sherman H.M., Marcus M.U., Ehrhardt J.C. Cardiac size and function in acromegaly. Circulation. 56:1977;863-869.
5. Hradec J., Marek J., Petrasek J. The nature of cardiac hypertrophy in acromegaly an echocardiographic study . Cor Vasa. 30:1988;186-199.
6. Hradec J., Marek J., Kral J., Janota T., Poloniecki J., Malik M. Long-term echocardiographic follow-up of acromegalic heart diasease. Am J Cardiol. 72:1993;205-210.
7. Melmed S. Acromegaly. N Engl J Med. 322:1990;966-977.
8. Ezzat S., Snyder P.J., Young W.F., Boyajy L.D., Newman C., Klibanski A., Molitch M.E., Boyd A.E., Sheeler L., Cook D.M., Malarkey W.B., Jackson I., Vance M.L., Thorner M.O., Barkan A., Frohman L.A., Melmed S. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med. 117:1992;711-718.
9. Lim M.J., Barkan A.L., Buda A.J. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med. 117:1992;719-726.
10. Marek J., Hana V., Krsek M., Justova V., Catus F., Thomas F. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol. 131:1994;20-26.
11. Devereux R.B., Alonso D.R., Lutas E.M., Gottlieb G.J., Campo E., Sachs I., Reichek N. Echocardiographic assessment of left ventricular hypoertrophy comparison to necropsy findings . Am J Cardiol. 57:1986;450-458.
12. Gilbert P.L., Siegel R.J., Melmed S., Sherman C.T., Fischbein M.C. Cardiac morphology in rats with growth hormone-producing tumours. J Mol Cell Cardiol. 17:1985;805-811.
13. Turner J.D., Rotwein P., Novakofski J., Bechtel P.J. Induction of mRNA for IGF-I and -II during growth hormone-stimulated muscle hypertrophy. Am J Physiol. 255:1988;E513-E517.
14. Ross D.A., Wilson C.B. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas in a series of 214 patients. J Neurosurg. 68:1988;854-867.
15. Theusen L., Christensen S.E., Weeke J., Orskov H., Henningsen P. The cardiovascular effects of octreotide treatment in acromegaly an echocardiographic study . Clin Endocrinol. 30:1989;619-625.
16. Tokgozoglu S.L., Erbas T., Aytemir K., Akalin S., Kes S., Oram E. Effects of octreotide on left ventricular mass in acromegaly. Am J Cardiol. 74:1994;1072-1074.
17. Giustina A., Boni E., Romanelli G., Grassi V., Giustina G. Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol. 75:1995;1042-1047.
18. Chanson P., Timsit J., Masquet C., Warnet A., Guillausseau P.J., Birman P., Harris A.G., Lubetzki J. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med. 113:1990;921-925.
19. Legrand V., Beckers A., Pham V.T., Demoulin J.C., Stevenaert A. Dramatic improvement of severe dilated cardiomyopathy in an acromegalic patient after treatment with octreotide and transsphenoidal surgery. Eur Heart J. 15:1994;1286-1289.
20. Baldelli R., Minniti G., Iacobellis G., Bultrini A., Paoloni A., Tamburrano G. Effects of lanreotide therapy on echocardiographic parameters in acromegalic patients (abstr). J Endocrinol Invest. 20:(suppl):1997;198.
21. Manelli F, Boni E, Desenzani P, Cappelli C, Damiani P, Doga M, Mascardi C, Negrini F, Grassi V, Giustina A. Short-term effects of a single slow release lanreotide injection on cardiovascular response to exercise in patients with active acromegaly (abstr). J Endocrinol Invest1997;20:(suppl):73.